Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

Autoimmune Disease Models

Reduce technical risk with rigorously validated, publication-ready models (e.g., BSA+CCL4+LPS-induced IgA Nephropathy) and TurboKnockout™-engineered efficiency (60% faster gene editing). Ethically optimized designs align with 3R principles to streamline IND-enabling studies.
Clinical Predictability
Achieve 85% translational concordance with IND-enabling histopathology and cytokine data.
Target Validation
Uncover novel pathways using gene-engineered models (e.g., TLR2 KO) with tissue-specific promoters.
Precision Drug Profiling
Test candidate efficacy and immune safety in models pre-validated with human biomarkers (e.g., Th17/Treg ratios).
Overview
Product
FAQs
Overview
Customizable Autoimmune Models: Compliant, Fast, Publication-Ready
Cyagen supports autoimmune disease research and therapeutic development with established induced mouse models, including collagen-induced arthritis (CIA) models for rheumatoid arthritis research and experimental autoimmune encephalomyelitis (EAE) models for multiple sclerosis studies. We also provide genetically engineered mouse models for investigating immune pathways such as Toll-like receptor signaling. Our end-to-end services cover model design, generation, disease induction, phenotyping, efficacy evaluation, and study-ready data delivery.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Be Also Interested In
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
Autoimmune & Inflammation
Advancing autoimmune drug discovery with models and efficacy data.
Oncology CRO Platform
End-to-end preclinical oncology support from models to IND data
Rodent Breeding
Scalable colony expansion with full genotyping support
Rodent Phenotyping
Full-spectrum analysis for rodents model
Cryopreservation & Recovery
Preserve and revive rodent strains on demand
Product
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Quantity
Main Area of Research
Additional Comments
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Selection Made Simple
Access Our Model Library >>
Base Strain
Catalog Number
Catalog NumberNameBase StrainResearch ApplicationAction
C001893AG129129S2/SvPasCyaInvestigating the pathogenesis and developing vaccines for arboviruses such as DENV, ZIKV, YFV, and CHIKV; Studying antiviral immune responses, interferon stimulation, and JAK-STAT signaling.
C001891A129 (Ifnar1 KO)129S2/SvPasCyaInvestigating the pathogenesis and developing vaccines for arboviruses such as DENV, ZIKV, YFV, and CHIKV; Studying antiviral immune responses, interferon stimulation, and JAK-STAT signaling.
I001220B6-hPCSK9/Apoe KOC57BL/6CyaDevelopment, screening, and preclinical evaluation of PCSK9-targeted drugs; Research on metabolic diseases such as hyperlipidemia, stroke, coronary heart disease, familial hypercholesterolemia (FH), and other atherosclerotic cardiovascular diseases (ASCVD).
C001713B6-hIL2RAC57BL/6NCyaIL2RA-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. Tumor immunology and other anti-tumor research.
C001693B6-H11-hBDCA2 (hCLEC4C)C57BL/6NCyaScreening, development, and preclinical efficacy evaluation of CLEC4C-targeted drugs; Study of pathological mechanisms and therapeutic methods for autoimmune disorders; Study of pathological mechanisms and therapeutic methods for hematological malignancies.
C001535BALB/c-Zap70*W163C (SKG)BALB/cAnCyaResearch on T cell signal transduction; Research on rheumatoid arthritis (RA); Research on ankylosing spondylitis (AS); Research on other autoimmune diseases.
I002079B6-hLPA(CKI)/Alb-cre/hPCSK9C57BL/6NCyaHyperlipidemia, stroke, coronary heart disease, familial hypercholesterolemia (FH), and other atherosclerotic cardiovascular diseases (ASCVD); Development and evaluation of targeted drugs against human Lp (a) and PCSK9.
I001143B6-hPD-1/hCTLA4C57BL/6NCyaPD-1/CTLA4-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of cancers and chronic viral infections.
C001837B6-hTL1A/hIL23AC57BL/6N;6JCyaScreening and development of TL1A/IL23A-targeted therapeutics, and preclinical pharmacodynamic and safety evaluations; Research on the pathological mechanisms and therapeutic strategies for allergic and inflammatory diseases, immune-related disorders, and cancer.
C001781B6-hCD40/hCD40LGC57BL/6NCyaScreening, development, and preclinical evaluation of CD40/CD40L-targeted drugs; Research on the pathological mechanisms and therapeutic approaches of autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN); Research on various malignant tumors; Research on cardiovascular diseases and neurological diseases.
Items: 1 to 10 of 147
1
2
3
4
5
6
...
14
15
Previous Page
Next Page
FAQs
Frequently Asked Questions (FAQs)
Are histopathological benchmarks included for clinical correlation?
Yes. Synovial inflammation scoring (H&E, Safranin O) and CNS demyelination indices (LFB/PAS) adhere to MIATA/ARRIVE guidelines, with pathologist-verified severity scales.
How are comorbidities (e.g., IBD dysbiosis) controlled?
Defined microbiota diets, cohousing, and antibiotic regimens isolate autoimmune mechanisms. 16s rRNA sequencing and lamina propria profiling distinguish primary pathology.
Do models replicate human immune responses for IND submissions?
Yes. HLA-transgenic models (HLA-DR3/4) and PBMC/human cytokine systems mimic human responses, pre-validated for MHC-II–peptide interactions and checkpoint inhibitor studies.
How do you ensure long-term model stability (e.g., NOD mice)?
≥10 generations of backcrossing, SNP monitoring, and cryopreservation minimize drift. Phenotypic checkpoints (insulitis scoring, autoantibody titers) ensure consistency.
How do your models replicate human autoimmune biomarkers (e.g., lupus)?
Validated using disease-specific biomarkers: Th17/Treg ratios (flow cytometry), serum autoantibodies (anti-dsDNA), and cytokine panels (IL-17, TNF-α). Immune profiling (CD4+ T cells, B220+ B cells) aligns with human pathologies like SLE or RA.
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research